Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06794645 · ClinicalTrials.gov registry record · Phase 2
Pembrolizumab and Pemetrexed for Progressive Chordoma
A Phase 2 study of Chordoma and Chordomas, sponsored by Saint John's Cancer Institute.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 21
- Enrollment target
- 1
- Study location
NCT06794645 is a Phase 2 study of Chordoma and Chordomas that is actively recruiting participants, run by Saint John's Cancer Institute. The registered enrollment target is 21 participants, below the 86-participant average among 15 other Chordoma trials with a reported enrollment target (76% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06794645, a Phase 2 study of Chordoma and Chordomas, is actively recruiting participants, sponsored by Saint John's Cancer Institute.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 21 participants
- Enrollment target
- 1
- Study location
Study Summary
Primary Objective: 1\. To determine objective response rate (ORR) according to RECIST v1.1 of pembrolizumab and high-dose pemetrexed in the treatment of patients with chordoma until disease progression. The OOR will be investigator assessed. Secondary Objectives: 1. To describe the adverse events associated with administering pembrolizumab and high-dose pemetrexed combination treatment. 2. To determine disease control rate based on imaging and overall survival. 3. To determine median PFS and PFS rates at 6, 9, 12, and 18 months. 4. To evaluate changes in volumetric tumor measurements based on imaging. 5. To determine the effects of combination treatment on quality of life, assessed by the EORTC-QLQ-C30 questionnaire. 6. To assess tumor evolution over time in patients with chordoma based on imaging, and molecular profiling. 7. To assess the pharmacodynamic effects of treatment in blood. Exploratory Objective: 1\. To explore the relationship between molecular phenotype and patient response.
Interventions
- DRUG Pembrolizumab
- DRUG Pemetrexed Phase 2
Study Locations (1)
California
- Providence Saint John's Health Center - Santa Monica
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2025-01 |
| Est. Completion | 2026-11-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06794645
The ClinicalTrials.gov registry entry for NCT06794645 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 86-participant average among 15 other Chordoma trials with a reported enrollment target (76% lower). The listed sponsor is Saint John's Cancer Institute, which has 19 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Chordoma appearing as the primary indexed condition, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT06794645 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT06794645 about?
NCT06794645 is a clinical study titled "Pembrolizumab and Pemetrexed for Progressive Chordoma". Primary Objective: 1\. To determine objective response rate (ORR) according to RECIST v1.1 of pembrolizumab and high-dose pemetrexed in the treatment of patients with chordoma until disease progression. The OOR will be investigator assessed. Secondary Objectives: 1. To describe the adverse events...
What is the current status of trial NCT06794645?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 21 participants. The study started on 2025-01. Estimated completion is 2026-11-30.
What conditions does trial NCT06794645 study?
This clinical trial studies the following conditions: Chordoma, Chordomas.
What interventions are being tested in trial NCT06794645?
The interventions under investigation include: Pembrolizumab (DRUG), Pemetrexed Phase 2 (DRUG).
Who is sponsoring clinical trial NCT06794645?
This trial is sponsored by Saint John's Cancer Institute, which has 19 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06794645 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chordoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Cetuximab for the Treatment of Advanced Unresectable or Metastatic Chordoma
ACTIVE NOT RECRUITING · Phase 2
-
Proton Beam Therapy for Chordoma Patients
ACTIVE NOT RECRUITING · Phase 2
-
Children and Adults With Chordoma
RECRUITING
-
Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors
RECRUITING · Phase 1
-
Tazemetostat+Nivo/Ipi in INI1-Neg/SMARCA4-Def Tumors
RECRUITING · Phase 1
-
Comparing Carbon Ion Therapy, Surgery, and Proton Therapy for Management of Pelvic Sarcomas Involving the Bone
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.